Inhibition of pEGFR in paired tumour biopsies from TKI treatment‐naïve EGFR mutant NSCLC patients treated with gefitinib (EGFR inhibitor) or gefitinib in combination with durvalumab (anti‐PD‐L1): 60PD

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Thoracic Oncology

• Publication date

  2016-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S1556-0864(16)30173-3PMID 27198416
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• A multi-functional core-shell surface-enhanced Raman scattering nanosensor for simultaneous imaging of epidermal growth factor receptor on cell membranes and ROS secreted from living cells

  2024cites this paper
• 免疫检查点抑制剂在驱动基因阳性晚期非小细胞肺癌中的应用进展

  2021cites this paper
• Durvalumab in non-small-cell lung cancer patients: current developments.

  2018cites this paper
• Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)

  2018cites this paper
• Durvalumab for the treatment of non-small cell lung cancer

  2018cites this paper
• Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer

  2017cites this paper
• Effects of gefitinib on quality of life and expression of inflammatory cytokines, T cell subsets and serum tumor markers in senile patients with NSCLC

  2017cites this paper
• Durvalumab: First Global Approval

  2017cites this paper